Acute kidney injury (AKI) is common in dogs and is associated with high morbidity and mortality. How to enhance kidney recovery is the main question in the management of our patients that develop AKI. Monitoring of treatment response is currently based on serum creatinine levels, a biomarker of kidney function.
The aim of this study is to describe urinary Neutrophil-‐Gelatinase-‐Associated Lipocalin (uNGAL), urinary NGAL to Creatinine Ratio (UNCR) and serum creatinine in dogs recently diagnosed with AKI and follow their progression during the first 3 days of therapy.
The ultimate goal of our study is to determine if uNGAL and/or UNCR as a biomarker of kidney damage will provide a better assessment of kidney recovery and a better monitoring tool for the treatment response in every day clinical practice in comparison with serum creatinine levels.
Dogs either presenting to our hospital or hospitalized patients that develop AKI within 48 hours of monitoring.
The dogs will have to have a urine analysis and culture prior to any antibiotic treatment
Dogs already started on any type of treatment for less than 24 hours will be included.
The dogs will require hospitalization for at least 3 days after the diagnosis of AKI and initiation of treatments.
Body weight greater than 5 kg.
Dogs with AKI diagnosed/already treated for more than 24 hours.
Dogs with AKI related to post-‐renal obstruction or neoplastic infiltration.
The study will cover the costs of the additional daily serum creatinine (measured every 12 hours for 3 days instead of every 24 hours), the costs of the urine creatinine measured every 12 hours for 3 days and the costs of the urinary NGAL measured every 12 hours for 3 days. These tests will not be performed immediately. Your dog’s participation will allow us to gain information regarding the levels of this new biological marker which may help in the management of other dogs with this condition in the future. You understand that your animal’s participation in this study will not improve or cure his/her condition.
For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: email@example.com
Is Your Pet Eligible?
If you believe that your pet may be eligible for this study, please complete our prescreening questionnaire for owners.
If you believe you have a patient who is eligible for this clinical trial study or you would like additional information from the Clinical Trials Office at the Cummings Veterinary Medical Center, complete a referring physician questionnaire.